FDA Greenlights Phase 2 Trial of TPX-115 Cell Therapy for Rotator Cuff Tears
Key Insights
Tego Science (search) receives FDA approval for Phase 2 (search) clinical trial of TPX-115, an allogeneic dermal-derived fibroblast therapy for rotator cuff partial tears.
The randomized, double-blind study will enroll 60 patients with Ellman grade 2 partial thickness rotator cuff tears (search) across multiple U.S. medical institutions.
The trial targets a $13.1 billion global market with no current cure, marking a significant advancement as the therapy moves directly to Phase 2 (search) without Phase 1 trials in the U.S.
Tego Science (search) has achieved a significant milestone as the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for TPX-115, an innovative cell therapy targeting rotator cuff partial labral tears. The approval, received within approximately one month of submission, enables the company to proceed with Phase 2 (search) clinical trials in the United States.
Trial Design and Patient Population
The upcoming study is designed as a randomized, double-blind, placebo-controlled trial that will span approximately 15 months. The trial will recruit around 60 adult patients across multiple U.S. medical institutions, focusing on individuals with MRI-confirmed Ellman grade 2 or ≤50% partial thickness rotator cuff tears (search) (PTRCT) who have not responded to conservative treatment approaches.
TPX-115, an allogeneic dermal-derived fibroblast therapy, will be administered as a single intratendinous injection under ultrasound guidance. The study's primary endpoint will assess changes in the Constant-Murley Scale (CMS) score at 24 weeks post-treatment, providing a comprehensive evaluation of shoulder function and pain levels.
Development Status and Market Potential
The therapy has already demonstrated promising results in South Korea, where Tego Science (search) has completed a Phase 1/2 (search) study and is currently conducting Phase 2b/3 (search) trials. The FDA's decision to allow direct progression to Phase 2 (search) trials in the U.S. without requiring Phase 1 studies suggests confidence in the therapy's safety profile.
"In a 19 trillion won ($13.1 billion) market with no cure globally, an allogeneic cell therapy has entered phase 2 (search) without phase 1," stated Tego Science (search) CEO Jeon Sae-wha. "We will significantly expand our cell therapy business through the successful U.S. clinical trial of TPX-115."
Clinical Significance
The development of TPX-115 addresses a significant unmet medical need in orthopedics. Rotator cuff tears (search) represent a common and debilitating condition that can severely impact patient quality of life and functionality. The progression of this cell therapy into Phase 2 (search) trials marks an important step toward potentially providing a novel treatment option in a field where current therapeutic options are limited.